Background Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit
1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a …

Chronic activation of the type I interferon (IFN) pathway plays a critical role in systemic lupus
erythematosus (SLE) pathogenesis. Anifrolumab is a human monoclonal antibody to the …

Objective To investigate long‐term safety and tolerability of anifrolumab, a human
monoclonal antibody to the type I interferon (IFN) receptor subunit 1, in patients with …

Journal Club Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al.
Anifrolumab, an anti‐interferon‐α receptor monoclonal antibody, in moderate‐to‐severe …

Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …

Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …

Objectives To characterise the efficacy and safety of anifrolumab in patients with systemic
lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic …

Objective To explore long‐term safety and tolerability of anifrolumab 300 mg compared with
placebo in patients with systemic lupus erythematosus (SLE) who completed a Treatment of …

Objective In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type
I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We …

Objective This post hoc analysis compared anifrolumab 300 mg every 4 weeks with placebo
on rash and arthritis measures with different stringency in patients with moderate to severe …